Verrica Pharmaceuticals Inc. · NASDAQ:VRCA
Verrica Pharmaceuticals — Technical Presentation (January 2020)
5 slides from Verrica Pharmaceuticals's technical presentation, Jan 20, 2020
Slide 1: Responder Characteristics in Molluscum Contagiosum Subjects Treated with VP-102 Achieving Complete Clearance
Responder Characteristics in Molluscum Contagiosum (MC) Subjects Treated with VP-102 Achieving Complete Clearance: Pooled Results of Two Phase 3 Multicenter, Randomized, Vehicle-Controlled Trials for the Topical Treatment of MC Lawrence F. Eichenfield1, Steven R. Cohen2, Janice L. Pelletier3, Pieter
Slide 2: Background and Methods
Background and Methods • VP-102 is a proprietary drug-delivery device combination containing a % of Subjects by Complete vs. Non-Complete topical formulation of cantharidin (0.7% w/v) under investigation for the Lesion Clearance treatment of molluscum contagiosum (MC). • In this post-hoc analysis, V
Slide 3: Baseline Demographics and Medical Histories Were Similar Between Groups
Baseline Demographics and Medical Histories Were Similar Between Groups
Slide 4: Safety Outcomes Were Similar Between VP-102 Groups
Safety Outcomes Were Similar Between VP-102 Groups • Application site treatment-emergent adverse events (TEAEs) were expected due to the pharmacodynamic action of cantharidin, a topical vesicant. • The overall rates of TEAEs due to treatment were similar between the CC and NC groups. • There were tw
Slide 5: Conclusions
Conclusions • In this study of subjects with MC treated with VP-102, baseline demographics and MC histories were similar between those who achieved complete clearance of all baseline and new lesions (CC) at the EOS visit compared to those who did not (NC). • Safety outcomes were similar in both grou
Verrica Pharmaceuticals — Technical Presentation (January 2020) on 6ix